Author

S. Pagan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Publicover· 2 shared M. Collin· 2 shared V. Bigley· 2 shared A. Burnett· 1 shared A. Dickinson· 1 shared A. Grech· 1 shared A. J. Simpson· 1 shared A. K. Long· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Publicover

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Donor monocyte-derived macrophages promote human acute graft versus host disease

L. Jardine, U. Cytlak, M. Gunawan, G. Reynolds, K. Green, X.-N. Wang, S. Pagan, M. Pradnya, C. A. Lamb, A. K. Long, E. Hurst, S. Nair, G. Jackson, A. Publicover, V. Bigley, , M. Collin

The paper identifies donor monocyte-derived macrophages as key players in human acute graft versus host disease, showing their enhanced activation of T cells and secretion of inflammatory cytokines.

bioRxiv · Sep 30, 2019Immunology

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

P. Milne, C. Wilhelm-Benartzi, M. R. Grunwald, V. Bigley, A. Publicover, S. Pagan, H. Marr, G. Jones, A. Dickinson, A. Grech, A. Burnett, N. Russell, M. Levis, S. Knapper, M. Collin

This paper shows that serum Flt3L levels correlate with progenitor cell mass and prognosis in AML, with lower levels linked to worse outcomes and relapse.

bioRxiv · Mar 25, 2019Cancer Biology